Flaherty KR, et al. - In this 24-week, single-arm, open-label Phase IV study, researchers investigated if treatment with pirfenidone (1602–2403 mg/day) and nintedanib (200–300 mg/day) is safe and tolerable in patients with idiopathic pulmonary fibrosis (IPF) with forced vital capacity (FVC) ≥50% and carbon monoxide diffusing capacity (DLco) ≥30%. With regards to the treatment regimen, nintedanib was started after patients had received pirfenidone for ≥16 weeks and tolerated a stable dose of ≥1602 mg/day for ≥28 days. Findings revealed this treatment regimen (combined pirfenidone and nintedanib use for 24 weeks) was tolerable in the majority of patients with IPF and was associated with a similar pattern of treatment-emergent adverse events expected for either treatment alone.